SGMO Logo

Sangamo Therapeutics, Inc. (SGMO) 

NASDAQ
Market Cap
$409.99M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
708 of 774
Rank in Industry
390 of 432

Largest Insider Buys in Sector

SGMO Stock Price History Chart

SGMO Stock Performance

About Sangamo Therapeutics, Inc.

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops …

Insider Activity of Sangamo Therapeutics, Inc.

Over the last 12 months, insiders at Sangamo Therapeutics, Inc. have bought $0 and sold $0 worth of Sangamo Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Sangamo Therapeutics, Inc. have bought $103,280 and sold $2.17M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 6,784 shares for transaction amount of $25,029 was made by Markels John () on 2022‑06‑03.

List of Insider Buy and Sell Transactions, Sangamo Therapeutics, Inc.

2023-09-26Sale10 percent owner
6M
2.4552%
$0.50$3M-17.84%
2022-08-29Sale
500,000
0.3203%
$5.31$2.66M-46.48%
2022-06-03Purchase
6,784
0.0045%
$3.69$25,029-5.24%
2022-06-01Purchase
5,000
0.0034%
$3.60$17,996-0.28%
2021-12-28Sale10 percent owner
2,764
0.002%
$8.51$23,522-41.00%
2021-12-27Sale10 percent owner
600
0.0004%
$8.56$5,136-41.81%
2021-12-23Sale10 percent owner
81,187
0.0555%
$8.55$694,530-44.06%
2021-12-09Sale10 percent owner
23,660
0.0171%
$8.56$202,541-38.39%
2021-12-08Sale10 percent owner
75,814
0.0515%
$8.64$654,828-42.32%
2021-12-07Sale10 percent owner
52,178
0.036%
$8.52$444,437-40.32%
2021-11-26Sale10 percent owner
28,884
0.0202%
$8.60$248,434-37.99%
2021-03-23SaleEVP, General Counsel & Sec.
17,524
0.0128%
$13.13$230,042-23.91%
2020-12-31SaleEVP, Technical Operations
2,464
0.0018%
$16.74$41,247-32.51%
2020-12-24SaleEVP, Technical Operations
3,331
0.0025%
$18.13$60,391-40.20%
2020-12-17Saledirector
10,000
0.0074%
$13.27$132,747-19.51%
2020-03-19Saledirector
35,000
0.0295%
$6.00$210,000+79.12%
2020-03-18Purchasedirector
3,000
0.0024%
$5.20$15,585+97.48%
2020-03-17Purchasedirector
5,000
0.0039%
$4.99$24,950+99.55%
2020-03-16Saledirector
15,000
0.0154%
$6.02$90,261+116.83%
2020-03-13Purchasedirector
5,000
0.0037%
$5.67$28,350+63.57%

Insider Historical Profitability

0.89%
RA CAPITAL MANAGEMENT, LLC
1829426
0.8768%
$1.973148<0.0001%
LANPHIER EDWARD O IIPresident & CEO
235000
0.1126%
$1.97142+107.09%
Wolff Henry WardExec VP & CFO
197872
0.0948%
$1.97129+107.09%
PARKER H STEWART
48700
0.0233%
$1.9740+23.16%
Markels John
32484
0.0156%
$1.9710<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Wasatch Advisors$13.49M9.720.13M+62.38%+$5.18M0.07
Armistice Capital Llc$11.37M8.1716.96MNew+$11.37M0.04
BlackRock$8.9M6.413.28M-5.8%-$548,376.45<0.0001
The Vanguard Group$8.18M5.8812.2M-3.17%-$267,249.60<0.0001
Acadian Asset Management$3.31M2.384.94M+4.05%+$128,859.650.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.